TQB3702 tablets

DRUG4 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Hematologic MalignancySystemic Lupus Erythematosus

Phase 1

Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Hematologic Malignancy

Start: 2022-11-30End: 2024-08-31Target: 137Updated: 2022-11-09

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

Not yet recruitingNCT06211751

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Hematologic Malignancy

Start: 2024-01-31End: 2026-06-30Target: 208Updated: 2024-01-18

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects

RecruitingNCT06448273

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Systemic Lupus Erythematosus

Start: 2024-07-19End: 2024-10-31Target: 40Updated: 2024-08-12

Phase 2

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

Not yet recruitingNCT06859931

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Systemic Lupus Erythematosus

Start: 2025-03-31End: 2026-12-31Target: 120Updated: 2025-03-05